Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.50−1.16 (-6.22%)
Close on Nov 12, 2026Market cap $127.13MP/E –Yield –
Cue Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cue Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$97.31M. For fiscal 2025 it was -$25.59M. The highest annual figure on record is -$25.59M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.59M | – |
| FY2024 | Dec 31, 2024 | -$41.10M | – |
| FY2023 | Dec 31, 2023 | -$51.59M | – |
| FY2022 | Dec 31, 2022 | -$52.30M | – |
| FY2021 | Dec 31, 2021 | -$42.45M | – |
| FY2020 | Dec 31, 2020 | -$43.99M | – |
| FY2019 | Dec 31, 2019 | -$35.96M | – |
| FY2018 | Dec 31, 2018 | -$37.94M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$87.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.79M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.54M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.57M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.72M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.73M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.90M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.03M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.22M | – |
See a number that looks wrong?